Comparing Medium-Term Clinical Outcomes following XEN® 45 and XEN® 63 Device Implantation

Table 2

Preoperative (baseline) and postoperative (for each follow-up visit) intraocular pressure (IOP), visual field mean deviation (MD), retinal nerve fiber layer (RNFL) thickness, and number of IOP-lowering medications required by the patient for XEN® 45 and XEN® 63 Gel Stent. Significance threshold was set at 0.05.

Measurement time point	N (number of eyes) XEN® 45/XEN® 63	XEN® 45 mean value (range)	XEN® 45 (vs. preop values)	XEN® 63 Mean value (range)	XEN® 63 (vs. preop values)	(XEN® 45 vs. XEN® 63 values)
IOP (mmHg)
Preop (baseline)	40/34	18,02 ± 5,23 (10 to 40)	—	19,00 ± 6,11 (11 to 36)	—	0,459
12 months	40/34	13,81 ± 1,88 (9 to 18)	≤0.001	15,47 ± 2,45 (20 to 9)	≤0.001	0,002
24 months	37/30	14,80 ± 2,23 (11 to 21)	≤0.001	14,66 ± 2,45 (7 to 20)	≤0.001	0,827
36 months	30/30	14,62 ± 1,90 (12 to 18)	≤0.001	15,46 ± 2,48 (9 to 20)	≤0.001	0,191
Visual field-Mean deviation (MD)
Preop (baseline)	40/30	9,97 ± 6,12 (0,6 to 23,10)	—	10,42 ± 7,16 (-1,2 to 25,70)	—	0,777
12 months	32/30	8,98 ± 6,80 (0,0 to 24,60)	0,679	8,01 ± 5,56 (0,7 to 18,30)	0,549	0,606
24 months	30/29	10,57 ± 6,88 (1,3 to 22,80)	0,375	8,64 ± 5,94 (0,5 to 21,80)	0,067	0,353
36 months	30/24	9,10 ± 5,52 (0,3 to 16,20)	0,700	7,59 ± 6,36 (-2,0 to 18,8)	0,685	0,437
Nerve fiber layer (microns)
Preop (baseline)	39/30	63,94 ± 11,42 (36 to 89)	—	59,58 ± 14,91 (36 to 89)	—	0,195
12 months	20/30	61,40 ± 10,13 (41 to 83)	0,881	62,50 ± 8,56 (44 to 79)	0,501	0,721
24 months	20/28	57,92 ± 8,15 (47 to 74)	0,064	62,15 ± 10,12 (50 to 92)	0,221	0,217
36 months	20/24	61,60 ± 10,09 (49 to 87)	0,924	64,81 ± 13,44 (41 to 94)	0,383	0,418
Number of glaucoma medications
Preop (baseline)	40/34	1,60 ± 0,94 (0 to 3)	—	1,64 ± 0,77 (0 to 3)	—	0,854
12 months	40/34	0,48 ± 0,78 (0 to 2)	≤0.001	0,41 ± 0,78 (0 to 2)	≤0.001	0,696
24 months	35/30	0,41 ± 0,71 (0 to 2)	≤0.001	0,33 ± 0,71 (0 to 2)	≤0.001	0,672
36 months	36/30	1,00 ± 0,87 (0 to 2)	≤0.001	0,46 ± 0,81 (0 to 2)	≤0.001	0,059